StreetInsider.com News Articles

Incyte to Present at Upcoming Investor Conferences

Tue, 01 Sep 2026 08:00:00 -0400

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:

21st Annual Wells Fargo Healthcare Conference on Wednesday, September 9, 2026 at 11:00 a.m. EDT
Cantor Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 9:45 a.m. EDT
Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 12:20 p.m. EDT

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte
Incyte is redefining what’s possible in biopharmaceutical innovation.

Incyte to Present at Upcoming Investor Conferences

Tue, 01 Sep 2026 08:00:00 -0400

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:

21st Annual Wells Fargo Healthcare Conference on Wednesday, September 9, 2026 at 11:00 a.m. EDT
Cantor Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 9:45 a.m. EDT
Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 12:20 p.m. EDT

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte
Incyte is redefining what’s possible in biopharmaceutical innovation.

H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Tue, 01 Sep 2026 07:12:14 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $150.00 price target on Incyte (NASDAQ: INCY).

The analyst commented: "Incyte entered a participation agreement (GENEROUS) with the Centers for Medicare and Medicaid Services (CMS) that enables participating state Medicaid programs to access Jakafi/Jakafi XR at prices aligned with a defined group of advanced industrialized nations; management places Medicaid exposure <4.5%, left FY26 Jakafi/Jakafi XR guidance at $3.22-$3.27B, and does not expect a material impact on its outlook. Applying the 4.5% ceiling to guidance implies less than ~$145-147M of annual Medicaid sales subject to the agreement. Medicaid already receives statutory rebates,

BMO Capital Reiterates Market Perform Rating on Incyte (INCY)

Tue, 01 Sep 2026 04:02:37 -0400

BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $130.00 price target on Incyte (NASDAQ: INCY).

The analyst comments "Voluntary CMS agreement removes potential policy overhang for Incyte with limited anticipated impact to the Jakafi franchise. The agreement announced today will give state Medicaid programs access to Jakafi/Jakafi XR at prices aligned with industrialized nations, while exempting Incyte from certain future CMS pricing mandates (e.g., GUARD/GLOBE). In addition to some pricing protection, management expects limited financial impact to Jakafi/Jakafi XR revenues (<4.5% headwind), maintaining FY26 guidance and long-term outlook. All in, we view today's agreement as an incremental

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

Thu, 27 Aug 2026 18:00:00 -0400

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.